This is a preview of subscription content, log in via an institution to check access.
Notes
The study was supported by Merck & Co. Inc.
Reference
Zhang D, et al. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States. Clinical Infectious Diseases : 19 Jan 2018. Available from: URL: http://doi.org/10.1093/cid/cix1021
Rights and permissions
About this article
Cite this article
Economic burden of primary and recurrent C. difficile infection. PharmacoEcon Outcomes News 796, 13 (2018). https://doi.org/10.1007/s40274-018-4687-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4687-7